Right ventriculo-arterial coupling - independent predictor of all-cause long-term mortality in heart failure with preserved ejection fraction

View at publisher
Authors: Caterina Delcea, S R Pitigoi, Dorin Ionescu, R E Martin-Graur, A M Muste, C A Buzea, G A Dan, Elisabeta Bădilă
Cited by: 0

Abstract

Abstract Introduction The interdependence between the right ventricular (RV) systolic force and the RV afterload defines the RV-pulmonary artery coupling (RVPAC). The echocardiographically derived ratio between tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP) has been proposed as a noninvasive surrogate method to assess RV-PA coupling (RVPAC) and has been reported as an independent prognostic marker in heart failure (HF) with reduced ejection fraction (HFrEF). Although elevated PASP is a common complication in HF with preserved ejection fraction (HFpEF), however limited data exist on the predictive value of RV-PA uncoupling in this population. Purpose To evaluate the prognostic role of the TAPSE/PASP ratio as a surrogate marker of RV-PA uncoupling in patients with HFpEF. Methods We conducted a retrospective cohort study including adult patients with HFpEF consecutively admitted to our cardiology department between January 2019 and December 2020. We excluded cases with acute coronary syndrome, pulmonary embolism, inflammatory bowel disease, autoimmune disorders, repeated admissions of the same patient, in-hospital death, and absence of necessary echocardiographic data from the index admission. All-cause mortality was assessed in October 2024, with a mean follow-up duration of 4 years. Receiver operating characteristic (ROC) analysis was used to determine optimal cut-off values, sensitivity (Se), and specificity (Sp), based on the Youden index. Results Our study sample included 121 HFpEF patients (mean age 72.21±9.68 years, 61.78% female). Long-term all-cause mortality was 29.26%. The mean TAPSE/PASP ratio was 0.65±0.32 mm/mmHg. ROC analysis showed significant associations with all-cause mortality for: TAPSE/PASP (AUC 0.76, 95% CI 0.68–0.83, cut-off ≤0.46, Se 69.44%, Sp 80.23%, p39 mmHg, Se 66.67%, Sp 80.23%, p

Fields of Study & Subjects

Cardiovascular Function and Risk Factors Heart Failure Treatment and Management Cardiac Valve Diseases and Treatments

Publication details

Journal / source
European Heart Journal - Cardiovascular Imaging
Volume
27
Issue
Supplement_1
Publication date
1 January 2026
Language
EN